Jazz spending spree has ups and downs


Jazz Pharmaceuticals has agreed with Aerial Bio Pharma to acquire the rights to ADX-N05, a drug designed to treat narcolepsy. The agreement sees an initial payment of $125 million (£76 million) in cash, plus up to $270 million dependent on development and revenue milestones. Aerial announced positive results for phase IIb trials of ADX-N05 and had been publicly seeking a buyer to oversee the next phase of the drug’s development.

However, Jazz’s proposed takeover of Italian drugmaker Gentium appears to be in jeopardy. Jazz had agreed with Gentium's board to acquire a controlling stake in the company in a deal that was initially valued at around $1 billion. The sale has been rejected by the company’s shareholders, who are now taking legal action against the board of Gentium on the grounds that they have undervalued the company and filed misleading and false documents with the Securities and Exchange Comission. In October 2013, Gentium received authorisation from the European commission to market DNA-based drug Defitelio (defibrotide), for treating severe hepatic veno-occlusive disease in patients undergoing haematopoietic stem cell transplants.

Both of these proposed transactions have increased ongoing speculation that Jazz is itself likely to become a target for further mergers and acquisitions activity, as it becomes more attractive to prospective buyers.


Related Content

Following her passion

11 January 2013 Research

news image

Veronique Gouverneur tells Marie Cote about fabulous fluorine and her next challenge

What are you afraid of?

29 October 2013 Feature

news image

The public’s mistrust of ‘chemicals’ will take great efforts to repair. Katharine Sanderson looks at the ‘c’-word

Most Read

Better batteries with pure lithium anodes

28 July 2014 Research

news image

Protective carbon nanosphere coating overcomes lithium problems, pointing the way to improved capacity

Takeover battle pushes Allergan to cut R&D jobs

28 July 2014 Business

news image

Besieged by serially acquisitive Valeant, the Botox maker will lay off 1500 staff to propel earnings growth

Most Commented

Isoamyl acetate

30 July 2014 Podcast | Compounds

news image

It makes a sweet banana-flavoured treat, but can ruin home brewed beer; Jenna Bilbrey introduces isoamyl acetate

Relativity behind mercury's liquidity

21 June 2013 Research

news image

First evidence that relativistic effects are indeed responsible for mercury's low melting point